Pazhani Sundaram
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2016First federal award
$7.0MFederal grants as PI12 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
12 awards · $7.0M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 5, 2025 | NIH | SBIR Phase II Novel Extracorporeal Device 'Amytrapper' To Remove Beta Amyloid In Alzheimer'sDisease | $625K | Recombinant Technologies LLC |
| Jul 19, 2024 | NIH | SBIR Phase II Novel Extracorporeal Device 'Amytrapper' To Remove Beta Amyloid In Alzheimer'sDisease | $784K | Recombinant Technologies LLC |
| Sep 25, 2023 | NIH | SBIR Phase II Novel Extracorporeal Device 'Amytrapper' To Remove Beta Amyloid In Alzheimer'sDisease | $807K | Recombinant Technologies LLC |
| May 20, 2020 | NIH | SBIR Phase II Novel Extracorporeal Device 'Amytrapper' To Remove Beta Amyloid In Alzheimer's Disease | $592K | Recombinant Technologies LLC |
| Sep 12, 2019 | NIH | SBIR Phase II Novel Extracorporeal Device 'Amytrapper' To Remove Beta Amyloid In Alzheimer's Disease | $165K | Recombinant Technologies LLC |
| May 24, 2019 | NIH | SBIR Phase II Novel Extracorporeal Device 'Amytrapper' To Remove Beta Amyloid In Alzheimer's Disease | $475K | Recombinant Technologies LLC |
| May 10, 2018 | NIH | SBIR Phase II SMALL MOLECULE THERAPY FOR ALZHEIMER'S DISEASE | $519K | Recombinant Technologies LLC |
| Sep 23, 2017 | NIH | SBIR Phase II Small molecule therapy for Alzheimer's Disease | $139K | Recombinant Technologies LLC |
| Aug 23, 2017 | NIH | SBIR Phase I Novel extracorporeal device 'Amytrapper' to remove beta amyloid in Alzheimer's Disease. | $148K | Recombinant Technologies LLC |
| Apr 26, 2017 | NIH | SBIR Phase II SMALL MOLECULE THERAPY FOR ALZHEIMER'S DISEASE | $519K | Recombinant Technologies LLC |
| May 15, 2016 | NIH | SBIR Phase II SMALL MOLECULE THERAPY FOR ALZHEIMER'S DISEASE | $1.7M | Recombinant Technologies LLC |
| May 13, 2016 | NIH | SBIR Phase II SMALL MOLECULE THERAPY FOR ALZHEIMER'S DISEASE | $519K | Recombinant Technologies LLC |
Peer ranks
Federal funding#148
Awards as PI#97
Patents#505
Companies
- Recombinant Technologies LLCLinked by awards · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.